Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: A comprehensive review of 45-year trends in intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) in the United States has not been published. Given their rising incidence, our study aimed to analyze trends in incidence and survival, comparing ICC and ECC.

Methods: We extracted a 45-year dataset (1975-2020) from the Surveillance, Epidemiology, and End Results database. Age-adjusted incidence rates were calculated using SEERStat®. Annual Percent Change (APC) was estimated via weighted least squares. Relative survival (1- and 5-year) was calculated using the Ederer II method and compared across sexes and races.

Results: A significant rise in ICC and ECC incidence was observed in both sexes (APC 3.71 for ICC vs. 6.16 for ECC; P<0.001). In females, ECC incidence increased more than ICC (APC 5.96 vs. 4.09, P<0.05), whereas males showed a fluctuating ECC trend and a steady ICC rise. Survival rates significantly improved across all races and sexes (P<0.05). ICC survival rose from 17.45% to 41.41% (1-year) and 2.83% to 10.99% (5-year), while ECC increased from 30.33% to 41.12% (1-year) and 5.96% to 10.44% (5-year). Among white and other-race females, ECC showed less improvement than ICC. Black individuals lacked statistically significant data.

Conclusions: Our study highlights disparities in ICC and ECC incidence, with higher rates in males, but better survival for ECC in males and ICC in females. The underrepresentation of Black individuals warrants further study to explore contributing factors such as risk, access to care, and treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928894PMC
http://dx.doi.org/10.20524/aog.2025.0951DOI Listing

Publication Analysis

Top Keywords

extrahepatic cholangiocarcinoma
8
forty-five-year trends
4
trends intra-
4
intra- extrahepatic
4
cholangiocarcinoma sex-
4
sex- race-based
4
race-based insights
4
insights background
4
background comprehensive
4
comprehensive review
4

Similar Publications

Hepatic reactive lymphoid hyperplasia diagnosed through post-ablation liver tumor biopsy.

Clin J Gastroenterol

September 2025

Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Hepatic reactive lymphoid hyperplasia (RLH), also known as hepatic pseudolymphoma, is a rare benign condition that predominantly affects middle-aged-to-elderly women and is often associated with autoimmune disorders. The imaging features of hepatic RLH frequently mimic those of malignant hepatic tumors, such as hepatocellular carcinoma (HCC), cholangiocarcinoma, or metastatic liver tumors, making its diagnosis based solely on imaging modalities challenging, often leading to unnecessary surgical resection. However, the optimal diagnostic strategy for hepatic RLH remains controversial.

View Article and Find Full Text PDF

Cholangiocarcinoma (CCA) remains a major public health concern in Thailand, particularly in areas endemic for Opisthorchis viverrini infection. During the period of 2020-2022, there was a rapid shift in public communication behaviors that created new opportunities to promote health education through diverse media channels. This study aimed to assess public awareness of CCA prevention and explore the feasibility of applying social marketing strategies during a time of health crisis.

View Article and Find Full Text PDF

Intrahepatic cholangiocarcinoma (iCCA) incidence is increasing globally and is associated with poor prognosis. Surgical resection remains the main curative treatment. However, many patients present with unresectable disease or underlying liver dysfunction, precluding resection.

View Article and Find Full Text PDF

Background: Cholangiocarcinomas have a poor prognosis, and resection is the only curative-intent treatment. We examined time-trends in mortality risk after resection in a nationwide Danish cohort.

Methods: We identified all Danish citizens diagnosed with cholangiocarcinoma in 2004-2022 who subsequently underwent liver resection, biliary tract resection, or a combination of the two.

View Article and Find Full Text PDF